指南与共识腹部CTMR

考虑临床-影像学高危特征重新评估现行指南:手术切除的胰腺黏液性囊性肿瘤与分支胰管型导管内乳头状黏液性肿瘤的对比研究

Comparison with surgically resected mucinous cystic neoplasm of pancreas and branch-duct type intraductal papillary mucinous neoplasm considering clinico-radiological high-risk features: a reassessment of current guidelines.
指南 / 共识 · Abdom Radiol (NY) · 2024-05-15

回顾性分析224例手术切除的胰腺黏液性囊性肿瘤(MCN,良性73例、恶性17例)与分支胰管型导管内乳头状黏液性肿瘤(BD-IPMN,良性110例、恶性24例)的临床影像特征,发现MCN恶性最优肿瘤大小阈值为8.95 cm(敏感度70.6%、特异度89%),高于指南建议的4.0 cm,提示需重新考虑MCN的指南阈值。

要点

  • MCN恶性最优肿瘤大小阈值为8.95 cm,特异度89%,优于指南建议的4.0 cm阈值。
  • 强化壁结节是MCN恶性强预测因子(OR 67.383),也是BD-IPMN恶性预测因子(OR 15.804)。
  • BD-IPMN中强化壁结节最优阈值为5.5 mm,对恶性鉴别最佳。

核心结论

  • 现行指南对BD-IPMN的管理可能合适,但MCN恶性最优阈值大小显著大于指南建议值,需重新考虑现有指南对MCN初始风险分层和管理的阈值。

研究设计与样本

  • 回顾性研究,纳入224例手术切除且病理确诊的MCN(良性73例、恶性17例)或BD-IPMN(良性110例、恶性24例)并有术前CT或MRI的患者。

关键影像表现/征象

  • MCN与BD-IPMN在肿瘤大小、位置、强化壁结节的存在及大小、壁或分隔增厚、多发性方面存在显著差异。
  • 多因素分析显示肿瘤大小(OR 1.336;95%CI 1.124-1.660,p=0.002)和强化壁结节存在(OR 67.383;95%CI 4.490-1011.299,p=0.002)是MCN恶性的显著预测因子。
  • BD-IPMN恶性预测因子为强化壁结节存在(OR 15.804;95%CI 4.439-56.274,p<0.001)和CA19-9升高(OR 19.089;95%CI 2.868-127.068,p=0.002)。

诊断标准与关键数值

  • MCN良恶性最优肿瘤大小阈值为8.95 cm,敏感度70.6%、特异度89%、PPV 27.6%、NPV 96.9%,特异度优于指南建议的4.0 cm阈值。
  • BD-IPMN中强化壁结节大小阈值为5.5 mm时对恶性鉴别最佳。
  • 高级别异型增生或浸润性癌定义为恶性,低级别异型增生定义为良性。

临床应用与阅片要点

  • 评估胰腺囊性肿瘤时需注意MCN与BD-IPMN在大小、位置、强化壁结节、壁/分隔增厚及多发性上的差异。
  • 对MCN,强化壁结节存在时恶性风险高(OR 67.383),应结合肿瘤大小综合评估。
  • 对BD-IPMN,强化壁结节≥5.5 mm及CA19-9升高提示恶性风险增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To perform a comparative analysis of surgically resected mucinous cystic neoplasm (MCN) of pancreas and branch-duct type intraductal papillary mucinous neoplasms (BD-IPMN) considering clinico-radiological high-risk predictors for malignant tumors using the current management guidelines.

MATERIALS AND METHODS: 224 patients who underwent surgical resection and had histopathologically confirmed MCNs (benign 73; malignant 17) or BD-IPMNs (benign 110; malignant 24) and had pre-operative CT or MRI were retrospectively reviewed. Tumors classified as either high-grade dysplasia or invasive carcinoma were considered malignant, whereas those with low-grade dysplasia were considered benign. Imaging features were analyzed by two radiologists based on selected high-risk stigmata or worrisome features proposed by prevalent guidelines except tumors with main pancreatic duct dilatation (> 5 mm) were excluded.

RESULTS: MCNs and BD-IPMNs showed significant differences in aspects like tumor size, location, the presence and size of enhancing mural nodules, the presence of wall or septal thickening, and multiplicity. Multivariate analyses revealed tumor size (OR, 1.336; 95% CI, 1.124-1.660, p = 0.002) and the presence of enhancing mural nodules (OR, 67.383; 95% CI, 4.490-1011.299, p = 0.002) as significant predictors of malignant MCNs. The optimal tumor size differentiating benign from malignant tumor was 8.95 cm, with a 70.6% sensitivity, 89% specificity, PPV of 27.6%, and NPV of 96.9%, demonstrating superior specificity than the guideline-suggested threshold of 4.0 cm. For malignant BD-IPMNs, the presence of enhancing mural nodules (OR, 15.804; 95% CI, 4.439-56.274, p < 0.001) and CA 19 - 9 elevation (OR, 19.089; 95%CI, 2.868-127.068, p = 0.002) as malignant predictors, with a size of enhancing mural nodule threshold of 5.5 mm providing the best malignancy differentiation.

CONCLUSION: While current guidelines may be appropriate for managing BD-IPMNs, our results showed a notably larger optimal threshold size for malignant MCNs than that suggested by current guidelines. This warrants reconsidering existing guideline thresholds for initial risk stratification and management of MCNs.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Kim H, Kim JH, An J, et al. Comparison with surgically resected mucinous cystic neoplasm of pancreas and branch-duct type intraductal papillary mucinous neoplasm considering clinico-radiological high-risk features: a reassessment of current guidelines. Abdom Radiol (NY). 2024. PMID: 38744705. doi:10.1007/s00261-024-04364-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。